Quest Diagnostics launches this month with tests for Investing.com’s Handshake

SECAUCUS, NJ – Quest Diagnostics (NYSE:NYSE:), an advanced diagnostic information provider, which was established by the U.S. Centers for Disease Control and Prevention (CDC) and has become the leading handle of transport and oropouche transfers. These Verträge sollen sicherstellen, the Quest die öffentlichen Gesundheitslabore schnell unterstützen kann, falls es zu einem Ausbruch ceser Infektionskrankheiten in der Bevölkerung kommt.

Providers performed a molecular laboratory test, Vogelgrippe-A-H5 virus in individuals who may then perform infection or the CDC criteria for testing. This test will take place at the end of October at the end of the clinical trial. He became a forced laborer of Quest in San Juan Capistrano, California, and he became durchgeführt.

Quest’s new test covers the Influenza-A-H5 ab virus, einschließlich A(H5N1), and includes tests for seasonal influenza A subtypes, influenza B and other infectious viruses. This is an infection problem or detection investigation of people who are currently in the course of a Vogelgrippe-A-H5 virus infection. Patient service centers seeking evidence of this test durchführen.

The current era is influenza A(H5N1) in the wild world and spring travel in the United States and breast milk is produced, with sporadic falls in males, usually domestically. Risks to the general economy are likely to be felt, and the CDC is concerned about the overall situation. Die Einführung des Tests von Quest wird es Ärzten ermöglichen, Vogelgrippe-Tests von einem nationalen kommerziellen Labor zu bestellen, has been möglicherweise den Zugang et la Testkapazität erhöht.

Zusätzlich zum Vogelgrippe-Test hat Quest also a CDC-Auftrag zur Entwicklung von Diagnostika for the Oropouche-Virus erhalten, un virus kommendes en America, par infizierte beißende Mücken et un inige Stechmückenarten auf den Menschen übertragen wird.

Dr. Yuri Fesko, Senior Vice President and Chief Medical Officer of Quest Diagnostics, announced the implementation of the corporate work process and the federal regional authorities for the reaction auf new auftretende Krankheiten. Elizabeth Marlowe, PhD, executive scientific director of Quest Diagnostics, led the CDC’s efforts to ensure the development of potential testing laboratories.

This reference is based on a news article from Quest Diagnostics.

In addition to the latest versions of Quest Diagnostics, you will also receive previous recommendations. The companies merged a significant quarter with an investment of 2.49 billion US dollars, resulting in a guarantee of 8.5% during the year, which took place during the organization of the period and life strategy. Laboratories. Quest Diagnostics analysts and operational agents have established an optimistic prognosis for the 2024 life cycle, with forecasts of 9.8 and 9.85 billion US dollars and an earnings from activity (EPS) of 9.8 billion 8.85 to 8.95 US dollars.

In analyst updates, Baird, a financial sector specialist, presents neutral research diagnostic activity on high outperformance and results on a positive overview of financial sector dynamics and larger trends. Of course, Leerink Partners took a preview of Quest Diagnostics and reached a price of 160-165 US dollars, which was a declaration of the 17th day of the EPS calendar for the month of October 2025.

In Bezug auf weitere Unternehmensnachrichten hat Quest Diagnostics Fortschritte bei seiner Marktpräsenz gemacht, insbesondere by the Übernahme von LifeLabs, die die Präsenz des unternehmens auf dem canadischen Markt erweiterte. The vorläufigen feedback from the directions for the 2025 life cycle defined a solid Grundlage for many people, who kept pace with employees and a high EPS panel with sustainable work tools for corporate projects. This is the first introduction to a quest diagnosis.

InvestingPro Erkenntnisse

The young Vertragsabschlüsse von Quest Diagnostics with the CDC go through the gut of their position as a leading player in the Gesundheitsdienstleister branch, like InvestingPro Tips. Hygiene measures for technicians, these measures for handshake testing and Oropouche virus for safety, are still relevant and state-of-the-art hygiene measures are not taken into account in the new verification procedures.

InvestingPro’s funding dates, with Quest Diagnostics having a market capitalization of US$17.64 billion, have been a bill in the market for broader diagnostic services. The agency of investors in the last dollar reached 9.54 billion US dollars, with an average of 2.6% in a simple trauma of time. This Wachstum, established with the new CDC-Verträgen, must now work with Quest aktiv within the Dienstleistungsangebot and within its Marktreichweite erweitert.

InvestingPro Tips is also available for Quest Diagnostics with a 13-year dividend and a 21-year dividend earned. This investment budget has a constant dividend rate which provides an attractive income, but which is not stable in the financial sector of this type. The current dividend yield stands at 1.91%, which represents an attractive investment in the stock market.

This is a Quest stock job that took place at 52 working hours, with a Kurs-Gewinn sale price of 19.82. This Commission should now be able to take an optimistic approach within the framework of corporate social protection, which will allow us to be better informed when the CDC-Verträge comes into force.

To learn more, analysis if interested, give us InvestingPro tips and advice. This article contains 10 more InvestingPro tips for Quest Diagnostics, the greatest context for the financial economy and business position of known companies.

This Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Please note that further information is required to provide additional information.